Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now official registry

Deep Vein Thrombosis clinical trials

Every US clinical trial registered for Deep Vein Thrombosis — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.

24 US clinical trials · 5 currently recruiting

The research picture

Deep Vein Thrombosis has 24 registered US clinical trials, 5 of them open to new participants right now — about 21% of the total.

5
recruiting participants now
21%
of trials open to enrollment
3
in Phase 3–4 (later-stage)
3
top sponsor: Brigham and Women's Hospital

Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.

Active & Recent Trials

RECRUITING NA 152,000 participants

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

Scott C. Woller, MD

NCT06232551

RECRUITING 500 participants

Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.

Mayo Clinic

NCT06519435

RECRUITING NA 500 participants

Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection

ThinkSono

NCT06652568

RECRUITING NA 30 participants

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

Medical University of South Carolina

NCT06451003

RECRUITING Early Phase 1 30 participants

Apixaban in Thrombocytopenia

Rushad Patell

NCT06886516

ACTIVE NOT RECRUITING NA 229 participants

BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

Penumbra

NCT05003843

ACTIVE NOT RECRUITING NA 225 participants

Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)

Washington University School of Medicine

NCT03250247

ACTIVE NOT RECRUITING Phase 4 145 participants

Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital

Inova Health Care Services

NCT07250763

COMPLETED NA 17,427 participants

Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events

Vanderbilt University Medical Center

NCT04574895

COMPLETED 10,679 participants

Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events

Thrombosis Research Institute

NCT02155491

COMPLETED 5,451 participants

Epidemiology of Venous Thromboembolism

Brigham and Women's Hospital

NCT00456196

COMPLETED Phase 3 692 participants

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Washington University School of Medicine

NCT00790335

COMPLETED NA 410 participants

D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

McMaster University

NCT00720915

COMPLETED NA 344 participants

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

Brigham and Women's Hospital

NCT00401414

COMPLETED Phase 3 300 participants

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United

NCT02585713

COMPLETED 271 participants

Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity

Abbott RDx Cardiometabolic

NCT01037270

COMPLETED 200 participants

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

University of Puerto Ri

NCT02345356

COMPLETED NA 100 participants

Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty

TriHealth

NCT02102828

COMPLETED Phase 2 80 participants

Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma

University of Utah

NCT03339349

COMPLETED NA 70 participants

Non-Interruptive Alerts for Improving Use of Clinical Decision Rules

University of Utah

NCT04702308

COMPLETED Phase 1 66 participants

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Daiichi Sankyo

NCT02303431

COMPLETED NA 40 participants

Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism

Brigham and Women's Hospital

NCT00413374

COMPLETED Phase 2 38 participants

Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)

University of Vermont

NCT01524653

COMPLETED NA 12 participants

Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)

University of North Carolina, Chapel Hill

NCT00858130

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 2
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Deep Vein Thrombosis Trial Landscape

ClinicalTrials.gov lists 24 US studies indexed under Deep Vein Thrombosis, and 5 of those are currently open to recruitment — roughly 21% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Deep Vein Thrombosis shows 3 late-stage studies (Phase 3 and Phase 4 combined) alongside 4 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Deep Vein Thrombosis is led by Brigham and Women's Hospital with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 24 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Deep Vein Thrombosis?

PlainTrial tracks 24 US clinical trials for Deep Vein Thrombosis, of which 5 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Deep Vein Thrombosis?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →